Company news

Hubei Jumpcan Pharmaceutical Co., Ltd news in 2025

Hubei Jumpcan Pharmaceutical Co., Ltd's news releases, calls and decks from 2025, newest first.

View company

Announcement on Shareholding of Top 10 Shareholders and Top 10 Holders of Shares Without Sales Limit Concerning Shares Repurchase

December 1, 2025

Announcement on Resolutions of the 19th Meeting of the 10th Board of Directors

November 24, 2025

Announcement on Implementation of Repurchase and Cancellation of Partial Restricted Stocks under 2022 Restricted Stock and Stock Option Incentive Plan

November 21, 2025

湖北济川药业股份有限公司关于全资子公司开立募集资金现金管理专用结算账户并利用闲置募集资金进行现金管理的进展公告

November 18, 2025

Announcement on Progress in Wholly-owned Subsidiaries Opening Special Settlement Account for Cash Management of Raised Funds and Using Idle Raised Funds for Cash Management

November 11, 2025

Report for Q3 2025

October 27, 2025

Announcement on Implementation of Independent Exercise in the 1st Exercise Period of Initially Granted Stock Options in 2022 Restricted Stock and Stock Option Incentive Plan

October 9, 2025

Announcement on Lifting Trading Restrictions and Listing of the 1st Trade Restriction Release Period of Initially Granted Restricted Stock under the 2022 Restricted Stock and Stock Option Incentive Plan

September 24, 2025

Announcement on Convening the 2025 Semi-annual Performance Briefing

September 23, 2025

Announcement on Resignation of Non-independent Director and Election of Employee Representative Director

September 19, 2025

Announcement on Obtaining Drug Registration Certificate by Subsidiary

September 16, 2025

Announcement on the Release of Pledge for Shares Held by the Controlling Shareholder

September 15, 2025

Indicative Announcement on Convening the 1st Extraordinary General Meeting in 2025

September 12, 2025

Indicative Announcement on the Use of Self-exercise for the 1st Exercise Period of Stock Options of Initial Grant under the 2022 Restricted Stock and Stock Option Incentive Plan

September 9, 2025

Announcement on Progress in Wholly-Owned Subsidiary’s Utilization of Idle Raised Capital for Cash Management, Redemption at Maturity, and Continued Cash Management

September 3, 2025

Announcement on Resolutions of the 16th Meeting of the 10th Board of Directors

August 22, 2025

Announcement on the Completion of Cancellation of Some Stock Options under the 2022 Restricted Stock and Stock Option Incentive Plan

August 7, 2025

Announcement on Completion of Share Delivery for Mr. Cao Fei's Tender Offer to Acquire the Company's Shares

July 31, 2025

Announcement on Release of Pledge of Partial Shares of Controlling Shareholders

July 21, 2025

Announcement on the Obtaining of the Drug Registration Certificate for the Collaborative Product Masiloxavir Tablets

July 20, 2025